Robert S. Lowe

2.2k total citations
49 papers, 1.7k citations indexed

About

Robert S. Lowe is a scholar working on Surgery, Plant Science and Epidemiology. According to data from OpenAlex, Robert S. Lowe has authored 49 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 13 papers in Plant Science and 12 papers in Epidemiology. Recurrent topics in Robert S. Lowe's work include Lipoproteins and Cardiovascular Health (18 papers), Pharmaceutical Economics and Policy (10 papers) and Virus-based gene therapy research (8 papers). Robert S. Lowe is often cited by papers focused on Lipoproteins and Cardiovascular Health (18 papers), Pharmaceutical Economics and Policy (10 papers) and Virus-based gene therapy research (8 papers). Robert S. Lowe collaborates with scholars based in United States, Canada and United Kingdom. Robert S. Lowe's co-authors include Paul M. Keller, Andrew M. Tershakovec, M. C. M. Pérombelon, Ronald W. Ellis, J. G. HARRISON, Andrew J. Davison, Jianxin Lin, Arvind Shah, Mary E. Hanson and Peter P. Tóth and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Clinical Endocrinology & Metabolism and Journal of Virology.

In The Last Decade

Robert S. Lowe

48 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert S. Lowe United States	25	599	545	331	228	220	49	1.7k
John E. Sagartz United States	26	93 0.2×	373 0.7×	53 0.2×	173 0.8×	651 3.0×	43	1.8k
Tahar van der Straaten Netherlands	29	152 0.3×	99 0.2×	40 0.1×	190 0.8×	714 3.2×	76	2.3k
James Tamura United States	20	177 0.3×	1.1k 2.0×	89 0.3×	523 2.3×	746 3.4×	39	2.4k
Carlos Penha‐Gonçalves Portugal	29	228 0.4×	513 0.9×	35 0.1×	708 3.1×	364 1.7×	111	2.2k
Hugh Salamon United States	19	754 1.3×	1.8k 3.3×	72 0.2×	728 3.2×	819 3.7×	34	3.1k
Karen A. Hunt United Kingdom	23	413 0.7×	397 0.7×	30 0.1×	673 3.0×	545 2.5×	43	2.4k
Victoria Anderson United States	25	150 0.3×	319 0.6×	261 0.8×	799 3.5×	325 1.5×	59	1.8k
Heather M. Smith United Kingdom	30	470 0.8×	2.0k 3.6×	55 0.2×	214 0.9×	844 3.8×	94	3.9k
Larry S. Schlesinger United States	30	311 0.5×	824 1.5×	30 0.1×	680 3.0×	720 3.3×	55	2.7k

Countries citing papers authored by Robert S. Lowe

Since Specialization

Citations

This map shows the geographic impact of Robert S. Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Lowe more than expected).

Fields of papers citing papers by Robert S. Lowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert S. Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Lowe. The network helps show where Robert S. Lowe may publish in the future.

Co-authorship network of co-authors of Robert S. Lowe

This figure shows the co-authorship network connecting the top 25 collaborators of Robert S. Lowe. A scholar is included among the top collaborators of Robert S. Lowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert S. Lowe. Robert S. Lowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kusters, D. Meeike, Maria Caceres, Claude Gagné, et al.. (2015). Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia. The Journal of Pediatrics. 166(6). 1377–1384.e3. 46 indexed citations

Constance, Christian, Ori Ben‐Yehuda, Nanette K. Wenger, et al.. (2014). Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years. Lipids in Health and Disease. 13(1). 13–13. 22 indexed citations

Robinson, Jennifer G., Christie M. Ballantyne, Willa A. Hsueh, et al.. (2013). Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Journal of clinical lipidology. 7(4). 292–303. 12 indexed citations

Bays, Harold, Maurizio Averna, Claudio Majul, et al.. (2013). Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia. The American Journal of Cardiology. 112(12). 1885–1895. 40 indexed citations

Morrone, Doralisa, William S. Weintraub, Peter P. Tóth, et al.. (2012). Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 223(2). 251–261. 204 indexed citations

Tóth, Peter P., Doralisa Morrone, William S. Weintraub, et al.. (2012). Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6-24 weeks. International Journal of Clinical Practice. 66(8). 800–812. 10 indexed citations

Davis, Harry R., Robert S. Lowe, & David Neff. (2011). Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis. 215(2). 266–278. 32 indexed citations

Bays, Harold, Michael H. Davidson, Rachid Massaad, et al.. (2011). Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Rosuvastatin in Patients With Hypercholesterolemia (the ACTE Study). The American Journal of Cardiology. 108(4). 523–530. 58 indexed citations

Foody, JoAnne M., W. Virgil Brown, Franklin J. Zieve, et al.. (2010). Safety and Efficacy of Ezetimibe/Simvastatin Combination Versus Atorvastatin Alone in Adults ≥65 Years of Age With Hypercholesterolemia and With or at Moderately High/High Risk for Coronary Heart Disease (the VYTELD Study). The American Journal of Cardiology. 106(9). 1255–1263. 20 indexed citations

10.

Bays, Harold, Scott Conard, Lawrence A. Leiter, et al.. (2010). Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. International Journal of Cardiology. 153(2). 141–147. 9 indexed citations

11.

Conard, Scott, Harold Bays, Lawrence A. Leiter, et al.. (2008). Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.. The American Journal of Cardiology. 102(11). 1489–1494. 62 indexed citations

12.

Cárdenas, Andrés, et al.. (2008). Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosis. Scandinavian Journal of Gastroenterology. 43(3). 328–333. 5 indexed citations

13.

Bradshaw, John E., Christine A. Hackett, Robert S. Lowe, et al.. (2006). Detection of a quantitative trait locus for both foliage and tuber resistance to late blight [Phytophthora infestans (Mont.) de Bary] on chromosome 4 of a dihaploid potato clone (Solanum tuberosum subsp. tuberosum). Theoretical and Applied Genetics. 113(5). 943–951. 35 indexed citations

14.

Shank-Retzlaff, Mary, Melissa Hamm, Martha Brown, et al.. (2005). Correlation between Mouse Potency and In Vitro Relative Potency for Human Papillomavirus Type 16 Virus-Like Particles and Gardasil® Vaccine Samples. Human Vaccines. 1(5). 191–197. 75 indexed citations

15.

Yeager, Mark D., Miguel Aste-Amézaga, Darron R. Brown, et al.. (2000). Neutralization of Human Papillomavirus (HPV) Pseudovirions: A Novel and Efficient Approach to Detect and Characterize HPV Neutralizing Antibodies. Virology. 278(2). 570–577. 43 indexed citations

16.

Cook, James C., Joseph G. Joyce, Hugh A. George, et al.. (1999). Purification of Virus-like Particles of Recombinant Human Papillomavirus Type 11 Major Capsid Protein L1 from Saccharomyces cerevisiae. Protein Expression and Purification. 17(3). 477–484. 90 indexed citations

17.

Bryan, Janine T., et al.. (1997). Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration. Journal of Medical Virology. 53(3). 185–188. 31 indexed citations

18.

Lowe, Robert S., Darron R. Brown, Janine T. Bryan, et al.. (1997). Human Papillomavirus Type 11 (HPV‐11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV‐11 Virus‐like Particles Expressed in Yeast. The Journal of Infectious Diseases. 176(5). 1141–1145. 105 indexed citations

19.

Neeper, Michael P., Robert S. Lowe, Stefan Galuska, et al.. (1996). Molecular cloning of an avian anti-Müllerian hormone homologue. Gene. 176(1-2). 203–209. 22 indexed citations

20.

Provost, P. J., Paul M. Keller, Hilton J. Klein, et al.. (1987). Successful infection of the common marmoset (Callithrix jacchus) with human varicella-zoster virus. Journal of Virology. 61(10). 2951–2955. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact